Deutsche Bank
TXG icon

Deutsche Bank’s 10x Genomics TXG Stock Holding History

Deutsche Bank’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.7M Sell
118,413
-18,280
-13% -$1.07M ﹤0.01% 977
2026
Q2 		$5.24M Buy
136,693
+20,826
+18% +$546K ﹤0.01% 1347
2026
Q1 		$2.46M Buy
115,867
+14,238
+14% +$285K ﹤0.01% 1667
2025
Q4 		$1.66M Sell
101,629
-62,564
-38% -$945K ﹤0.01% 1901
2025
Q3 		$1.92M Buy
164,193
+80,346
+96% +$1.05M ﹤0.01% 1794
2025
Q2 		$971K Buy
83,847
+75,082
+857% +$684K ﹤0.01% 2107
2025
Q1 		$76.5K Sell
8,765
-1,425
-14% -$18K ﹤0.01% 3280
2024
Q4 		$146K Buy
10,190
+2,657
+35% +$41.9K ﹤0.01% 3194
2024
Q3 		$170K Buy
7,533
+479
+7% +$9.9K ﹤0.01% 3001
2024
Q2 		$137K Buy
7,054
+451
+7% +$11.8K ﹤0.01% 3005
2024
Q1 		$248K Buy
6,603
+1,259
+24% +$55.3K ﹤0.01% 2721
2023
Q4 		$299K Sell
5,344
-6,171
-54% -$269K ﹤0.01% 2653
2023
Q3 		$475K Buy
11,515
+25
+0.2% +$1.3K ﹤0.01% 2205
2023
Q2 		$642K Buy
11,490
+987
+9% +$53.4K ﹤0.01% 2231
2023
Q1 		$586K Sell
10,503
-6,991
-40% -$326K ﹤0.01% 2403
2022
Q4 		$637K Buy
17,494
+9,657
+123% +$316K ﹤0.01% 2315
2022
Q3 		$223K Sell
7,837
-3,306
-30% -$126K ﹤0.01% 2885
2022
Q2 		$505K Sell
11,143
-98,325
-90% -$5.1M ﹤0.01% 2596
2022
Q1 		$8.33M Sell
109,468
-3,659
-3% -$320K ﹤0.01% 1173
2021
Q4 		$16.9M Sell
113,127
-26,701
-19% -$4.09M 0.01% 909
2021
Q3 		$20.4M Buy
139,828
+11,417
+9% +$1.96M 0.01% 895
2021
Q2 		$25.1M Buy
128,411
+44,065
+52% +$7.97M 0.01% 828
2021
Q1 		$15.3M Buy
84,346
+16,774
+25% +$2.9M 0.01% 998
2020
Q4 		$9.6M Buy
67,572
+65,446
+3,078% +$9.5M 0.01% 1061
2020
Q3 		$265K Sell
2,126
-175,606
-99% -$18.4M ﹤0.01% 3053
2020
Q2 		$15.9M Buy
177,732
+171,779
+2,886% +$13.4M 0.01% 782
2020
Q1 		$371K Hold
5,953
– – ﹤0.01% 2629
2019
Q4 		$453K Hold
5,953
– – ﹤0.01% 2774
2019
Q3 		$300K Buy
+5,953
New +$329K ﹤0.01% 2952

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Deutsche Bank's TXG Position: Q3 2026 in Review

Deutsche Bank reduced its 10x Genomics (TXG) stake by 13% in Q3 2026, selling an estimated $1.07M and leaving 118,413 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #977.

Deutsche Bank first reported a position in TXG in Q3 2019 and has held it in 29 quarters since. The position peaked at $25.1M in Q2 2021. 288 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Deutsche Bank held 118,413 shares of 10x Genomics worth $10.7M as of Q3 2026.
  • Deutsche Bank sold 18,280 10x Genomics shares in Q3 2026, an estimated $1.07M.
  • 10x Genomics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #977 holding.
  • Deutsche Bank first reported a position in 10x Genomics in Q3 2019 and has held it in 29 quarters since.
  • Deutsche Bank's 10x Genomics position peaked at $25.1M in Q2 2021.
  • 288 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.